Title: A Phase 2 multicenter open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS) non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS)

Study Overview

The purpose of this study is to assess of activity of eribulin mesylate in pediatric subjects with relapsed/refractory RMS, NRSTS or EWS.

Study Description

This study will be conducted as an assessment of the safety and preliminary activity of eribulin mesylate in pediatric participants with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), or Ewing sarcoma (EWS) to determine whether each cohort warrants further investigation


  • IRB Number: 1712550270 (PHO-PRADAN-EISAI-ADVL1722)
  • Research Study Identifier: TX9284
  • Principal Investigator: Kristy Pilbeam

Recruitment Status

Open

Contact the research team to learn more about this study.

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176